Pd Rx Pharmaceutical Stock Net Income
| PDRX Stock | USD 3.33 0.00 0.00% |
As of the 17th of February 2026, Pd-Rx Pharmaceutical owns the information ratio of 0.1222, and Market Risk Adjusted Performance of 7.72. In respect to fundamental indicators, the technical analysis model allows you to check possible technical drivers of Pd Rx Pharmaceutical, as well as the relationship between them.
Pd-Rx Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pd-Rx Pharmaceutical's valuation are provided below:Pd Rx Pharmaceutical does not right now have any fundamental measures for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Pd-Rx |
Pd-Rx Pharmaceutical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pd-Rx Pharmaceutical's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pd-Rx Pharmaceutical.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Pd-Rx Pharmaceutical on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Pd Rx Pharmaceutical or generate 0.0% return on investment in Pd-Rx Pharmaceutical over 90 days. Pd-Rx Pharmaceutical is related to or competes with Unidoc Health, and Devonian Health. PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the h... More
Pd-Rx Pharmaceutical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pd-Rx Pharmaceutical's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pd Rx Pharmaceutical upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1222 | |||
| Maximum Drawdown | 14.83 |
Pd-Rx Pharmaceutical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pd-Rx Pharmaceutical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pd-Rx Pharmaceutical's standard deviation. In reality, there are many statistical measures that can use Pd-Rx Pharmaceutical historical prices to predict the future Pd-Rx Pharmaceutical's volatility.| Risk Adjusted Performance | 0.1257 | |||
| Jensen Alpha | 0.2668 | |||
| Total Risk Alpha | 0.1685 | |||
| Treynor Ratio | 7.71 |
Pd-Rx Pharmaceutical February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1257 | |||
| Market Risk Adjusted Performance | 7.72 | |||
| Mean Deviation | 0.5313 | |||
| Coefficient Of Variation | 662.58 | |||
| Standard Deviation | 1.84 | |||
| Variance | 3.4 | |||
| Information Ratio | 0.1222 | |||
| Jensen Alpha | 0.2668 | |||
| Total Risk Alpha | 0.1685 | |||
| Treynor Ratio | 7.71 | |||
| Maximum Drawdown | 14.83 | |||
| Skewness | 7.81 | |||
| Kurtosis | 62.27 |
Pd Rx Pharmaceutical Backtested Returns
Pd-Rx Pharmaceutical appears to be slightly risky, given 3 months investment horizon. Pd Rx Pharmaceutical retains Efficiency (Sharpe Ratio) of 0.16, which implies the firm had a 0.16 % return per unit of price deviation over the last 3 months. We have found sixteen technical indicators for Pd-Rx Pharmaceutical, which you can use to evaluate the volatility of the company. Please evaluate Pd-Rx Pharmaceutical's information ratio of 0.1222, and Market Risk Adjusted Performance of 7.72 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Pd-Rx Pharmaceutical holds a performance score of 12. The company owns a Beta (Systematic Risk) of 0.0348, which implies not very significant fluctuations relative to the market. As returns on the market increase, Pd-Rx Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pd-Rx Pharmaceutical is expected to be smaller as well. Please check Pd-Rx Pharmaceutical's risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and day median price , to make a quick decision on whether Pd-Rx Pharmaceutical's current price history will revert.
Auto-correlation | 0.31 |
Below average predictability
Pd Rx Pharmaceutical has below average predictability. Overlapping area represents the amount of predictability between Pd-Rx Pharmaceutical time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pd Rx Pharmaceutical price movement. The serial correlation of 0.31 indicates that nearly 31.0% of current Pd-Rx Pharmaceutical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.31 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Pd Rx Pharmaceutical reported net income of 1.86 M. This is 99.46% lower than that of the Health Care Providers & Services sector and 99.09% lower than that of the Health Care industry. The net income for all United States stocks is 99.67% higher than that of the company.
Pd-Rx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pd-Rx Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pd-Rx Pharmaceutical could also be used in its relative valuation, which is a method of valuing Pd-Rx Pharmaceutical by comparing valuation metrics of similar companies.Pd Rx is currently under evaluation in net income category among its peers.
Pd-Rx Fundamentals
| Return On Equity | 0.25 | |||
| Return On Asset | 0.0556 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 4.45 M | |||
| Shares Outstanding | 1.72 M | |||
| Price To Earning | 3.33 X | |||
| Price To Sales | 0.40 X | |||
| Revenue | 21.6 M | |||
| Gross Profit | 6.96 M | |||
| EBITDA | 991.1 K | |||
| Net Income | 1.86 M | |||
| Cash And Equivalents | 104.55 K | |||
| Cash Per Share | 0.06 X | |||
| Total Debt | 466.84 K | |||
| Debt To Equity | 0.31 % | |||
| Current Ratio | 4.14 X | |||
| Book Value Per Share | 4.95 X | |||
| Cash Flow From Operations | (465.77 K) | |||
| Earnings Per Share | 1.08 X | |||
| Beta | -0.16 | |||
| Market Capitalization | 10.29 M | |||
| Z Score | 13.2 | |||
| Annual Yield | 0.11 % |
About Pd-Rx Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pd Rx Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pd-Rx Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pd Rx Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pd-Rx Pink Sheet Analysis
When running Pd-Rx Pharmaceutical's price analysis, check to measure Pd-Rx Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pd-Rx Pharmaceutical is operating at the current time. Most of Pd-Rx Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Pd-Rx Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pd-Rx Pharmaceutical's price. Additionally, you may evaluate how the addition of Pd-Rx Pharmaceutical to your portfolios can decrease your overall portfolio volatility.